Welcome to our dedicated page for Atyr Pharma news (Ticker: ATYR), a resource for investors and traders seeking the latest updates and insights on Atyr Pharma stock.
aTyr Pharma, Inc. develops clinical-stage biotechnology programs based on its proprietary tRNA synthetase platform. Its news centers on efzofitimod, a biologic immunomodulator in development for interstitial lung disease, including pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease.
Company updates commonly cover EFZO-FIT and EFZO-CONNECT study activity, FDA interactions, quarterly and annual financial results, research and development spending, healthcare conference presentations, and equity award grants under Nasdaq inducement rules.
aTyr Pharma (Nasdaq: ATYR) reported first quarter 2026 results and a corporate update. The company ended March 31, 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments.
aTyr will continue developing efzofitimod in pulmonary sarcoidosis, plans a new global Phase 3 trial after an FDA Type C meeting, and remains on track to complete enrollment in the Phase 2 EFZO-CONNECT SSc-ILD study in the first half of 2026.
aTyr Pharma (Nasdaq: ATYR) will participate in two investor conferences in New York in May and June 2026. Events include the RBC Capital Markets Global Healthcare Conference on May 20 with 1x1 meetings and the Jefferies Global Healthcare Conference on June 4 featuring a fireside chat.
A webcast and 90-day replay of the Jefferies presentation will be available on aTyr’s investor relations website.
aTyr Pharma (Nasdaq: ATYR) outlined its regulatory and clinical path for efzofitimod in pulmonary sarcoidosis after an FDA Type C meeting.
The company plans to submit an IND in June 2026 for a new global Phase 3 trial using FVC as the primary endpoint and KSQ-Lung as a key secondary endpoint in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
The 54-week, randomized, double-blind, placebo-controlled study is expected to enroll up to approximately 372 patients, with dosing every three weeks and stable background corticosteroid and/or immunosuppressant therapy.
aTyr Pharma (Nasdaq: ATYR) reported full-year 2025 results and a corporate update. The company ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. R&D expense was $60.2 million and G&A expense was $17.6 million.
The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, but 5.0 mg/kg efzofitimod showed clinical benefit on multiple secondary measures. A Type C meeting with the FDA is scheduled for mid-April 2026.
aTyr Pharma (Nasdaq: ATYR) disclosed inducement option grants dated February 17, 2026, awarding two new employees an aggregate of 12,200 nonstatutory stock options at an exercise price of $0.98 per share, equal to the closing price on that date.
Each option vests over four years (25% at one year, then monthly over three years) and was granted under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
aTyr Pharma (Nasdaq: ATYR) will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026 at 8:00 AM EDT. President and CEO Sanjay S. Shukla, M.D., M.S. will deliver a corporate presentation and meet one-on-one with registered investors.
A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days.
aTyr Pharma (Nasdaq: ATYR) said the FDA accepted a Type C meeting request to discuss efzofitimod for pulmonary sarcoidosis, scheduled for mid-April 2026. The company will review Phase 3 EFZO-FIT results and report meeting minutes afterwards.
The Phase 3 study enrolled 268 patients; it did not meet the primary endpoint of corticosteroid dose reduction at week 48, but 5.0 mg/kg efzofitimod showed statistically significant benefits on multiple patient-reported outcomes and maintained lung function, with a safety profile consistent with prior trials.
aTyr Pharma (Nasdaq: ATYR) announced that Sanjay S. Shukla, M.D., M.S., President and CEO, will present at the Piper Sandler 37th Annual Healthcare Conference in New York, December 2–4, 2025.
The presentation is scheduled for Tuesday, December 2, 2025 at 1:00 PM EST in a fireside chat format. Management will be available for one-on-one investor meetings for registered attendees. A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days. For investor inquiries, contact investorrelations@atyrpharma.com.
aTyr Pharma (NASDAQ:ATYR) reported third quarter 2025 results and clinical updates for efzofitimod. The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint of mean daily oral corticosteroid dose change at week 48, but 5.0 mg/kg showed improvements in multiple pre-specified efficacy measures and reduced steroid burden.
The company plans to meet with the FDA in Q1 2026 to review EFZO-FIT results and determine the path forward. Enrollment in the Phase 2 EFZO-CONNECT study for SSc-ILD is ongoing and expected to complete in H1 2026. Cash and investments were $92.9 million as of Sept 30, 2025; Q3 R&D was $22.1 million and G&A was $4.8 million.
aTyr Pharma (NASDAQ:ATYR) presented additional findings from its Phase 3 EFZO-FIT™ study of efzofitimod in 268 pulmonary sarcoidosis patients at the ERS Congress 2025. While the study missed its primary endpoint regarding oral corticosteroid dose reduction, the 5.0 mg/kg efzofitimod treatment group showed significant improvements in multiple secondary endpoints including:
The Fatigue Assessment Scale Total Score (p=0.0226) and King's Sarcoidosis Questionnaire-General Health score (p=0.0197) at week 48 versus placebo. The treatment also demonstrated improvements in KSQ-Lung score (p=0.0196), preservation of forced vital capacity, and maintained a well-tolerated safety profile.